GlassScriptPhysician profile
Stephen Neal
NPI 1609076538
$4,910.96
in general payments reported to CMS, 2019-2025
21 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $115 · 2022: $470 · 2023: $1,101 · 2024: $1,171 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,933 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,933.44 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,013.66 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $664.69 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $605.83 | 2019-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $540.95 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $393.33 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $374.93 | 2022-2025 | Caplyta |
| Lundbeck LLC | $277.19 | 2020-2025 | Rexulti |
| Corium, LLC | $264.08 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $186.49 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $182.45 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $135.78 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $72.90 | 2019-2022 | |
| Abbvie INC. | $55.97 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.22 | 2022 | |
| Almatica Pharma LLC | $19.65 | 2023 | Sertraline Hcl, Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.23 | 2023 | Quviviq |
| Sage Therapeutics, LLC | $17.14 | 2024 | |
| Azurity Pharmaceuticals, INC. | $14.06 | 2025 | Zonisade |
| Noven Therapeutics, LLC | $13.94 | 2024 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $13.16 | 2019 | |
| Organon LLC | $11.31 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Neal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.